← Back to home

LOCALLY ADVANCED OR METASTATIC KRAS G12C-MUTATED NSCLC WITH A PD-L1 EXPRESSION <1% OR A PD-L1 EXPRESSION ≥ 1% AND AN STK11 CO-MUTATION

Clinical trials for LOCALLY ADVANCED OR METASTATIC KRAS G12C-MUTATED NSCLC WITH A PD-L1 EXPRESSION <1% OR A PD-L1 EXPRESSION ≥ 1% AND AN STK11 CO-MUTATION explained in plain language.

Never miss a new study

Get alerted when new LOCALLY ADVANCED OR METASTATIC KRAS G12C-MUTATED NSCLC WITH A PD-L1 EXPRESSION <1% OR A PD-L1 EXPRESSION ≥ 1% AND AN STK11 CO-MUTATION trials appear

Sign up with your email to follow new studies for LOCALLY ADVANCED OR METASTATIC KRAS G12C-MUTATED NSCLC WITH A PD-L1 EXPRESSION <1% OR A PD-L1 EXPRESSION ≥ 1% AND AN STK11 CO-MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New hope for Tough-to-Treat lung cancer: experimental drug targets specific mutation

Disease control Ongoing

This study is testing an experimental drug called JDQ443 as the first treatment for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The trial will enroll 95 participants to see how well the drug shrinks tumors and how safe it i…

Matched conditions: LOCALLY ADVANCED OR METASTATIC KRAS G12C-MUTATED NSCLC WITH A PD-L1 EXPRESSION <1% OR A PD-L1 EXPRESSION ≥ 1% AND AN STK11 CO-MUTATION

Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control

Last updated Mar 09, 2026 14:22 UTC

LOCALLY ADVANCED OR METASTATIC KRAS G12C-MUTATED NSCLC WITH A PD-L1 EXPRESSION <1% OR A PD-L1 EXPRESSION ≥ 1% AND AN STK11 CO-MUTATION

Get alerted when new LOCALLY ADVANCED OR METASTATIC KRAS G12C-MUTATED NSCLC WITH A PD-L1 EXPRESSION <1% OR A PD-L1 EXPRESSION ≥ 1% AND AN STK11 CO-MUTATION trials appear

New hope for Tough-to-Treat lung cancer: experimental drug targets specific mutation